The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: A case-control association study

International Clinical Psychopharmacology

Volumn 25, Issue 4, 2010, Pages 218-227

  Kocabas, Neslihan Aygun ^a,b   Faghel, Carole ^a   Barreto, Mara ^a   Kasper, Siegfried ^a   Linotte, Sylvie ^a   Mendlewicz, Julien ^c   Noro, Magali ^a   Oswald, Pierre ^a   Souery, Daniel ^d   Zohar, Joseph ^e   Massat, Isabelle ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b FNRS   (Belgium)

^c GAZI UNIVERSITY   (Turkey)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e SHEBA MEDICAL CENTER   (Israel)

Author keywords

Antidepressant; Catechol O methyltransferase; Haplotype; Major depressive disorder; Single nucleotide polymorphisms; Treatment response phenotype

Indexed keywords

CATECHOL METHYLTRANSFERASE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ALLELE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MASS SPECTROMETRY; MOOD DISORDER; NEUROTRANSMISSION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; CASE-CONTROL STUDIES; CATECHOL O-METHYLTRANSFERASE; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 77953721854     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e328338b884     Document Type: Article

References (40)

1. Baune B, Hohoff C, Berger K, Neumann A, Mortensen S, Rohehrs T, et al. (2008). Association of the COMT val158met variant with antidepressant treatment response in major depression. Neuropsychopharmacology 33:924-932.
2. Benedetti F, Colombo C, Pirovano A, Marino E, Smeraldi E (2009). The Catechol O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting. Psychopharmacology 203:155-160.
3. Bialecka M, Kurzawski M, Klodowska-Duda G, Opala G, Tan EK, Drozdzik M (2008). The association of functional Catechol O-methyltransferase haplo-types with risk of Parkinson's disease, levodopa treatment response, and complications. Pharmacogenet Genomics 18:815-821.
4. Bray NJ, Buckland PR, Williams NM, Williams HJ, Norton N, Owen MJ, O'Donovon MC (2003). A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain. Am J Hum Genet 73:152-161.
5. Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, et al. (2004). Functional analysis of genetic variation in Catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 75:807-821.
6. DeMille MMC, Kidd JR, Ruggeri V, Palmatier MA, Goldman D, Odunsi A, et al. (2002). Population variation in linkage disequilibrium across the COMT gene considering promoter region and coding region variation. Hum Genet 111:521-537.
7. Dempster EL, Mill J, Craig IW, Collier DA (2006). The quantification of COMT mRNA in post mortem cerebellum tissue: diagnosis, genotype, methylation and expression. BMC Med Genet 7:10-17.
8. Diatchenko L, Slade GD, Nackley AG, Bhalang K, Sigurdsson A, Belfer I, et al. (2005). Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Molec Genet 14:135-143.
9. Drago A, De Ronchi D, Serretti A (2009). Pharmacogenetics of antidepressant response: an update. Hum Genomics 3:257-274.
10. Funke B, Malhotra AK, Finn CT, Plocik AM, Lake SL, Lencz T, et al. (2005). COMT genetic variation confers risk for psychotic and affective disorders: a case control study. Behav Brain Functions 1:19-28.
11. Gabriel SB, Shabalina SA, Tchivileva IE, Satterfield K, Korchynskyi O, Makarov SS, et al. (2002). The structure of haplotype blocks in the human genome. Science 296:2225-2229.
12. Gogos JA, Morgan M, Luine V, Santha M, Ogawa S, Pfaff D, Karayiorgou M (1998). Catechol O-methyltransferase deficit mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Nat Acad Sci 95: 9991-9996.
13. Gupta M, Bhatnagar S, Kaur H, Baghel R, Bhasin Y, Chauhan C, et al. (2009). Association studies of Catechol O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment. Pharmacogenomics 10:385-397.
14. Halleland H, Lindervold AJ, Halmoy A, Haavik J, Johansson S (2009). Association between Catechol O-methyltransferase (COMT) haplotypes and severity of hyperactivity symptoms in Adults. Am J Med Genet Part B 150:403-410.
15. Hosak L (2007). Role of COMT gene Val158Met polymorphism in mental disorders: a review. Eur Psychiatry 22:276-281.
16. Huotari M, Gogos JA, Karayiorgou M, Koponene O, Forsberg M, Raasmaja A, et al. (2002). Brain catecholamine metabolism in Catechol O-methyltransfer-ase deficit mice. Eur J Neurosci 15:246-256.
17. Illi A, Setälä-Soikkeli E, Kampman O, Viikki M, Nuolivirta T, Poutanen O, et al. (2010). Catechol-O-methyltransferase val108/158met genotype, major depressive disorder and response to selective serotonin reuptake inhibitors in major depressive disorder. Psych Research 176:85-87.
18. Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S, et al. (2009). A genome wide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry 66:966-975.
19. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM (1996). Human Catechol O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsy-chiatric disorders. Pharmacogenetics 6:243-250.
20. Laje G, McMahon FJ (2007). The pharmacogenetics of major depression: past, present and future. Biol Psychiatry 62:1205-1207.
21. Mannisto PT, Kaakkola S (1999). Catechol-O-methyltransferase (COMT) biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 51:593-628.
22. McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, et al. (2006). Variation in the gene encoding the Serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 78:804-814.
23. Meyer-Lindenberg A, Nichols T, Callicott JH, Ding J, Kolachana B, Buckholtz J, et al. (2006). Mol Psychiatry 11:867-877.
24. Michaelovsky E, Gothelf D, Korostishevsky M, Frisch A, Burg M, Carmel M, et al. (2007). Association between a common haplotype in the COMT gene region and psychiatric disorders in individuals with 22q11.2DS. Int J Neuropsycho-pharmacol 11:351-363.
25. Mier D, Kirsch P, Meyer-Lindenberg AM (2009). Neural substrates of pleiotropic action of genetic variation in COMT: a meta-analysis. Mol Psychiatry 1-10.
26. Mukherjee N, Kidd KK, Pakstis AJ, Speed WC, Li H, Tarnok Z, et al. (2010). The complex global pattern of genetic variation and linkage disequilibrium at catechol-O-methyltransferase. Mol Psychiatry 15:216-225.
27. Mulder RT, Joyce PR, Frampton CMA, Luty SE, Sullivan PF (2006). Six months of treatment for depression: outcome and predictors of course of illness. Am J Psychiatry 166:95-100.
28. Murray CJ, Lopez AD (2006). Evidence-based health policy-lessons from the Global Burden of disease study. Science 274:740-743.
29. Nackley AG, Shabalina SA, Tchivileva IE, Sattarfield K, Korchynskyi O, Makarov SS, et al. (2006). Human Catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 314:1930-1932.
30. Nackley AG, Shabalina SA, Lambert JE, Conrad MS, Gison DG, Sattarfield K, Diatchenko L (2009). Low enzymatic haplotypes of the human Catechol-O- methyltransferase gene: enrichment for marker SNPs. Plus One 4:e5237.
31. Palmer L, Cardon L (2006). Shaking the tree: mapping complex disease genes with linkage disequilibrium. Lancet 366:1223-1234.
32. Perlis RH, Fijal B, Adams DH, Sutton VK, Trivedi MH, Houston JP (2009). Variation in Catechol O-methyltransferase (COMT) is associated with duloxetine response in a clinical trial for major depressive disorder. Biol Psychiatry 65:785-791.
33. Reynolds GP (2007). The impact of pharmacogenetics on the development and use of antipsychotic drugs. Drug Discovery Today 12:953-959.
34. Shen LX, Basilion JP, Stanton VP (1999). Single-nucleotide polymorphisms can cause different structural folds of mRNA. Proc Natl Acad Sci 96: 7871-7876.
35. Shield AJ, Thomae BA, Eckloff BW, Wieben ED, Weinshilboum RM (2004). Human catechol O-methyltransferase genetic variation: gene resequencing and functional characterization of variant allozymes. Mol Psychiatry 9: 151-160.
36. Shifman S, Bronstein M, Sternfeld M, Pisante-Shalom A, Lev-Lehman E, Weinzman A, et al. (2002). A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 71:1296-1302.
37. Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, et al. (2007). Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry 68:1062-1070.
38. Szegedi A, Rujescu D, Tadic A, Muller MJ, Kohnen R, Stassen HH, Dahman N (2005). Catechol O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J 5:49-53.
39. Tenhunen J, Salminen M, Lundstrom K, Kiviluoto T, Savolainen M, Ulmanen I (1994). Genomic organisation of the human Catechol O-methyltransferase (COMT) gene and its expression from two distinct promoters. Eur J Biochem 223:1049-1059.
40. Tsai SJ, Gau YTA, Hong CJ, Liou YJ, Yu YWY, Chen TJ (2009). Sexually dimorphic effect of catechol O-methyltransferase (COMT) val158met polymorphism on clinical response to fluoxetine in major depressive patients. J Affect Disord 113:183-187.